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ABSRACT 
Single chain variable fragments (scFv) have widely been used in research, diagnosis and 
treatment, but the scFv is considered as difficult protein for expression in Escherichia coli (E. 
coli). In previous studies, we expressed a construction of recombinant single chain variable 
fragments again antigen specific for blood type A (antiA-scFv) individually or fused with Trx 
or SUMO. However, soluble fraction was low abandant and only approximately 40% when 
fused with Trx, the other cases were expressed in form of inclusion body. Therefore, it was 
difficult for purification, refolding and activity assessment. In this paper, we demonstrated a 
suitable construction for soluble production of antiA-scFv fused with SUMO (SUMO/antiA-
scFv) in presence of chaparones. Under fermentation with 0.1 mM IPTG at 20
o
C, the 
SUMO/antiA-scFv was entirely expressed in soluble form. Importantly, after cleavage from 
SUMO with SUMO protease, antiA-scFv was still maintained in the supernatant fraction. 
Therefore, it can help ensure bioactivity and is useful for purification process. To the best of 
our knowledge, this is the first report showing soluble recombinant scFv fused with SUMO in 
presence of chaperone for determination of blood group antigens. Thus, this result facilitates 
the optimal study of soluble expression, purification and bioactivity determination of the antiA-
scFv recombinant antibody.  
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INTRODUCTION 
Escherichia coli expression system is the 
most host of choice for producing 
heterologous protein because of high 
recombinant product level (Ni & Chen, 2009; 
Schmidt, 2004; Spadiut et al., 2014; Terpe, 
2006). Besides, genetic properties of E. coli 
have been well known. However, E. coli has 
some disadvantages, such as limitation of the 
recombinant protein secretion and formation 
of inclusion body leading to lost biological 
activity. 
For expression of antibody fragments, 
protein is produced in oxidized periplasmic 
space for correct disulfide bond formation 
(Skerra & Plückthun, 1988). Synthesis of the 
protein in reduced environment usually causes 
protein aggregate without activity (Wörn et 
al., 2000). Refolding of antibody fragment 
from the inclusion body form is generally 
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ineffective. Therefore, mutation of genes 
encoding glutathione and thioredoxin 
reductase in host strains, co-expression of 
chaperones such as GroEL/ES, DnaK/J, 
DsbC, Skp, GroES/L as well as other proteins 
have been investigated to enhance production 
of active recombinant proteins (Bothmann & 
Plückthun, 2000; de Marco, 2009; Friedrich et 
al., 2010; Golchin et al., 2012; Sonoda et al., 
2011; Yuan et al., 2013). 
SUMO based protein expression system 
produces high level of soluble recombinant 
protein in E. coli, yeast, mammal. When fused 
with SUMO, soluble accumulation of 
heterologous proteins are significantly 
enhanced (Butt et al., 2005, Marblestone et al. 
2006, Panavas et al., 2009). In addition, 
SUMO fused system is also more priority 
because enzyme SUMO protease has ability 
recognizing tertiary structure of SUMO and 
cleave generation of the recombinant protein 
with the desired N-terminus without addition 
of amino acid residues. Some findings 
showing that SUMO fused scFv for VEGF 
(Ye et al., 2008) and FGFR3 (Liu et al., 2015) 
was expressed in soluble form with 
bioactivity. 
In this study, we showed that the single 
chain variable fragment recognizing blood 
antigen (antiA-scFv) when fused with SUMO 
in present of chaperone in E. coli was 
efficiently expressed. The recombinant 
protein was almost soluble product. 
MATERIALS AND METHODS  
E. coli DH10b (Invitrogen, USA) was 
used for cloning genes. E. coli JM109, BL21 
(DE3) and Rosseta 2 (Invitrogen, USA) were 
used for gene expression. Plasmid 
pET22b+/antiA-scFv (GEL, IBT) was used as 
template for amplifying antiA-scFv. Plasmid 
pSUMOpro3 for gene expression in  
E. coli was purchased from LifeSensors, 
USA. Other chemicals, enzymes, 
antibodies were used in this study 
including: monoclonal antibody against C-
myc produced from mouse and anti-mouse 
IgG-peroxidase secondary antibody (Sigma, 
USA), APS, TEMED, Chloroform, Ethidium 
brobmide, Glucose, Glycerol, Glycine, 
Isoamyl-alcohol, Ethanol, Methanol, Peptone, 
Yeast Extract, SDS, Tris, Acrylamid, Bis 
Acrylamide, Agar, Agarose, Coomassie 
(Merck, Germany), KIT DNA GFX
TM
 (code 
28-9034-70, GE Healthcare Life Science, 
Englands), dNTP, Taq DNA polymerase, 
Dnase I, T4 DNA-ligase, restriction enzymes 
(Fermentas, USA), skim milk (Difco, USA), 
Ampiciline, TMB (Sigma, USA). 
Methods 
Amplification of antiA-scFv gene from 
pET22b+/antiA-scFv 
Gene antiA-scFv was amplified from 
pET22b+/antiA-scFv by PCR with following 
components: 18µl dH2O, 2.5µl buffer 10X, 
2.5µl dNTP 2 mM, 0.5µl F - BsaI 10 µM (5’-
TAGGTCTCTAGGTCAGGTCCAAGTGCA
GC-3’), 0.5µl R - XbaI 10 µM (5’-
TGTCTAGATTACAGGTCTTCTTCGC-3’), 
0.5µl pET22b+/antiA-scFv, 0.5µl Taq 
polymerase.  
PCR programmes: initial denaturation at 
95°C for 3 mins; 30 cycles of 3 steps: 
denaturation at 94°C for 30 sec, annealing at 
50°C for 30 sec, extension at 72°C for 60 sec; 
final extension at 72°C for 10 mins. 
Construction of expression vector 
pSUMO/antiA-scFv 
Amplified antiA-scFv gene was digested 
with two restriction enzymes BsaI and XbaI. 
Besides, vector pSUMOpro3 was also cleaved 
by BsaI. The gene fragment and vector 
products were purified using DNA Extraction 
Kit. After that, the gene and vector fragments 
were ligated using enzyme T4 ligase to  
creat recombinant expression vector 
pSUMO/antiA-scFv. Subsequently, the ligate 
solution was transformed into E. coli DH10b 
by heat shock method. The positive colonies 
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were selected on LB plates supplemented with 
100 µg/ml ampicillin (LBA) (Sambrook & W 
Russell 2001). Plasmids isolated from selected 
transformants were checked for harboring 
insert of antiA-scFv gene using restriction 
enzyme SacI. Finally, the constructed 
expression vector pSUMO/antiA-scFv was 
transformed into expression strains. 
Expression of antiA-scFv  
E. coli expression strains of BL21 (DE3), 
JM109 and Rosetta harboring expression 
vector pSUMO/antiA-scFv were inoculated 
into LBAmp with shaking 200 rpm at 37°C 
overnight. After that, the overnight culture 
was inoculated into fresh LBA medium at OD 
about 0.1 and continually incubated at 37°C 
with shaking 200 rpm to reach OD about 0.3 – 
0.5. The culture was induced with 0.1 mM 
isopropyl β- D- thiogalactopyranoside (IPTG) 
(Studier et al., 1990) and fermented at 20
o
C 
with shaking 200 rpm for 16 hours. After 
fermentation, the cells were harvested by 
centrifugation at 5000 rpm for 5 mins and 
resuspended in buffer 20 mM Tris-HCl, pH = 
8 to final OD600 = 10. 
Co-expression of chaperones and antiA-scFv 
in E. coli 
The E. coli recombinant strain harboring 
vectors expressing chaperone pG-KJE8 and 
antiA-scFv gene (pSUMO/antiA-scFv) was 
inoculated into LB medium with 100 µg/ml 
Amp and 20 µg/ml Cm (Chloramphenicol) 
with shaking at 200 rpm, 37°C for overnight. 
The overnight culture was inoculated into 
fresh LB medium (or PE) with Amp and Cm 
added chaperone-inducers including 0.5 
mg/ml L-arabinose and 5 µg/ml Tetracyline at 
OD = 0.1. The preculture was incubated at 
26°C with shaking at 200 rpm until OD600 
about 0.3–0.5. The culture was induced with 
0.1 mM IPTG and fermented at 20°C with 
shaking 200 rpm for 16 hours. After 
fermentation, the cells were harvested by 
centrifugation of 5000 rpm for 5 mins and 
resuspended in buffer 20 mM Tris-HCl, pH = 
8 to final OD600 = 10. 
Extraction of recombinant protein from  
E. coli  
The recombinant cells harvested from 
fermentation culture were resuspended in 
buffer 20 mM Tris HCl, pH=8 to an OD of 10. 
The cells were disrupted by sonication with 
Amplitude for 10 mins. After sonication, total 
soluble proteins were separated from pellet by 
centrifugation at 8000 g at 4°C for 15 mins.  
The pellet was resuspended in equivalent 
volume in 20 mM Tris HCl, pH=8 buffer. 
Proteins from soluble and insoluble fractions 
were checked by SDS-PAGE 12.6% 
(Laemmli 1970) . 
Cleavage of SUMO/antiA-scFv with SUMO 
protease  
One ml of the total soluble proteins was 
added with 5µl of enzyme SUMO protease 
0.76 mg/ml (provided by Genetic engineering 
lab). The reaction was carried out in 20 mM 
Tris HCl, pH = 8 buffer, added with 2 mM 
DTT and incubated at 30°C for 3 hours. 
Assessment of protein expression by  SDS-
PAGE and Western blot 
SDS-PAGE (Laemmli 1970) and Western 
blot was carried out as described in Dang et al 
(Dang et al., 2017). Briefly, recombinant 
protein SUMO/antiA-scFv was detected by 
Western blotting using monoclonal antibody 
against C-myc. After SDS-PAGE, proteins 
were transferred from gel to PVDF 
membrane. Subsequently, the blot was 
incubated with blocking buffer, then antibody 
against C-myc, afterward antimouse IgG-
peroxidase. Finally, the detection reaction was 
carried out in the TMB solution. 
RESULTS AND DISCUSSION 
In the previous paper, we reported the 
findings of expression of antiA-scFv in the 
construction with vector pET22b(+) in E. coli 
(Dang et al., 2017). Protein antiA-scFv was 
expressed in form of inclusion body. The 
antiA-scFv was purified in denaturation 
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condition and refolding in some buffers. 
However, the refolded protein showed lost 
biological activity for red blood cell 
aggregation. Besides, the protein was also 
expressed with signal peptide pelB/antiA-scFv 
for secretion at periplasm, but the 
recombinant protein was produced at low 
abundant and insoluble (data not shown). 
Therefore, we shifted to express the 
recombinant protein fused with some proteins 
such as TRX, SUMO to enhance production 
of soluble recombinant protein. When fused 
with TRX, soluble fraction was only about 
40% of total expressed recombinant protein 
(data submitted in Academia Journal of 
Biology). Following, we presented result on 
construction and expression of antiA-scFv 
fused with SUMO (SUMO/antiA-scFv) in 
presence of chaparones. SUMO/antiA-scFv 
was almost produced in soluble form. 
Construction of expression vector 
pSUMO/antiA-scFv 
An antiA-scFv gene was amplified from 
plasmid pET22b+/antiA-scFv using primer 
pairs F- BsaI and R-XbaI. PCR product was a 
clear single DNA fragment of 900 bps as 
expected size of antiA-scFv gene (Fig. 1a). 
In order to construct an expression vector 
pSUMO/antiA-scFv, firstly the PCR product 
was double digested with XbaI and BsaI and 
the vector was treated with BsaI to generate 
two compatible ends. Then, the cleavage 
products were purified and checked on 
agarose gel (Fig. 1b) afterward ligated 
together by T4 DNA ligase to generate 
pSUMO/antiA-scFv.  
 
Figure 1. Assessment of antiA-scFv gene and vector pSUMOpro3 
(a) PCR product amplifying antiA-scFv. (b) Cleavage products of antiA-scFv and vector 
pSUMOpro3 using restriction enzyme XbaI and BsaI. Lane M: DNA marker 1 kb (Fermentas). 
Lane 1: PCR product of antiA-scFv. Lane 2: Cleavage product of vector pSUMOpro3 using 
BsaI. Lane 3: Cleavage product of antiA-scFv using XbaI and BsaI 
 
Some transformants from ligation of 
pSUMOpro3 and antiA-scFv gene were 
selected to extract plasmids. The plasmids 
from transformants were higher than control 
plasmid of pSUMOpro3 (Fig. 2a). Result 
checking the plasmid using SacI showed that 
the recombinant plasmid harboring antiA-scFv 
generated two DNA bands. Theoretically, 
enzyme SacI has a sequence for recognizing 
in vector pSUMOpro3 and a site in antiA-
scFv gene, therefore when the recombinant 
plasmid treated with SacI to create the two 
bands of 400 bps and 6300 bps (Fig. 2b). 
Thus, we inserted antiA-scFv gene fragment 
into pSUMOpro3 (called pSUMO/antiA-
scFv). 
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Expression of fusion protein SUMO/antiA-
scFv  
pSUMO/antiA-scFv was transformed into 
E. coli strains including BL21, JM109, 
Origami, Rosseta 1, Rosseta 2 and Soluble. 
 
Figure 2. Creation of recombinant plasmid 
pSUMO/antiA-scFv 
(a) Plasmids extracted from transformants of 
pSUMO/antiA-scFv. (b) Cleavage product of 
pSUMO/antiA-scFv using SacI. Lane M: 
DNA marker 1 kb (Fermentas). Lane 1: vector 
pSUMOpro3. Lane 2, 3, 4, 5: plasmids from 
transformants pSUMO/antiA-scFv. Lane 6, 7: 
plasmid pSUMO/antiA-scFv before and after 
treated with SacI 
Recombinant strains were induced at OD 
= 0.6–0.8 with IPTG of 0.5 mM, incubation at 
30°C for 6 hours. Harvesting OD was not 
significantly different between the strains. In 
which, Rosseta 1, Rosseta 2 and JM109 well 
produced the recombinant protein with 
molecular weight of approximately 47 kDa 
higher than those produced by Origami strain. 
In contrast, Soluble strain had no visible band 
of SUMO/antiA-scFv. Moreover, the 
assessment of soluble recombinant protein 
showed that SUMO/antiA-scFv was produced 
inclusion body. Besides, the strains were also 
tested by fermentation in different media at 
lower temperatures (16°C and 20°C) and 
lower concentrations of IPTG. However, 
SUMO/antiA-scFv was still produced 
insoluble form (Fig. 3). Therefore, we decided 
to co-expression with chaperones. 
Co-expression of  SUMO/antiA-scFv and 
chaparone  
Recombinant proteins synthesized in E. 
coli were usually formed inclusion body due 
to process of folding correct structure as 
native protein. Accordingly, this is resulted 
the lost of biological activity. Although, we 
designed the construct in which the target 
gene was fused with a factor for enhancing 
solubility of recombinant protein such as 
SUMO. However, the enhancer was not 
always effect for every case. Thus, the 
requirement for optimum expression is to find 
the increasing amount of soluble target 
protein. In some situations, presence of some 
chaperones such as GroEL-GroES and DnaK-
DnaJ-GrpE had facilitated the precise folding 
and reduced inclusion body (Wang et al. 
2013, Young et al. 2004).  
 
Figure 3. Evaluation of SUMO/antiA-scFv 
expression in recombinant strains at 16°C 
R1. Rosseta 1, R2. Rosseta 2, J. JM109, M. 
protein marker, S, P. soluble and pellet 
fraction, respectively 
We used plasmid pGKJE8 that can produce 
chaperones GroEL- GroES and DnaK-DnaJ-
GrpE to co-express with SUMO/antiA-scFv in 
E. coli JM109. Protein chaperones were 
synthesized with estimated weight of 60, 10, 
70, 40 and 22 kDa for GroEL, GroES, DnaK, 
DnaJ and GrpE, respectively (Fig. 4). In 
presence of the chaperones, SUMO/antiA-scFv 
was produced with molecular weight of 47 
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scFv almost existed in a soluble form. 
Remarkably, after cleavage from SUMO, 
antiA-scFv with the weight of 33 kDa was still 
in soluble fraction (Figs 4 b, c). Thus, it was 
useful for recombinant protein purification. In 
contrast, absence of the chaperone, even at low 
temperature, SUMO/antiA-scFv was 
completely produced as inclusion body (Fig. 
3). In addition, we also emphasized that SUMO 
also supported to the soluble recombinant 
protein. Because co-expression of these 
chaperones and individual antiA-scFv 
produced insoluble form (date not shown). 
Thus, this was demonstrated that chaperone 
molecular primarily contributed to structural 
formation during the folding of SUMO/antiA-
scFv. In agreement, some findings showed that 
co-expression of chaperone enhances 
production of scFv recognizing TLH from a 
bacterium causing digestive diseases in human 
(Wang et al. 2013)  and scFv for BNP protein  
(Maeng et al., 2011).  
 
Figure 4. Analysis of SUMO/antiA-scFv co-expressed with chaperones 
(a) Evaluation of soluble and insoluble of SUMO/antiA-scFv, (b) Cleavage of SUMO/antiA-
scFv with SUMO protease, (c) Western blot. Lane M: Protein marker (Fermentas). Lane P, S,  
T: pellet, soluble, total fraction, respectively. Lane S/s, S/p: Soluble and pellet fractions of 
protein after treated with SUMO protease 
 
CONCLUSION 
Our data demonstrate that the expression 
of the antiA-scFv fused with SUMO in 
presence of chaperones was greatly increased 
soluble production. Thus, the results are 
useful basis for antiA-scFv purification 
process in E. coli for determination of blood 
types. 
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